BIOMAT Database Logo BIOMAT Database Logo

Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. 1998

A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II di Napoli, Naples, Italy. rpivone@tin.it

In this study, we report the clinical presentation, response to medical treatment, and long-term follow-up of 26 patients with prolactinoma (15 macro- and 11 micro-adenomas) diagnosed at the age of 7-17 yr. All patients were first treated with bromocriptine (BRC) at doses ranging from 2.5-20 mg/day orally. BRC was discontinued for intolerance and/or resistance to the drug and was replaced by quinagolide (CV) at doses ranging from 0.075-0.6 mg/day or by cabergoline at doses ranging from 0.5-3.5 mg/week orally. Two patients received external conventional radiotherapy after surgery. In 7 prepubertal males and 6 females with macroprolactinoma, headache and/or visual defects were the first symptoms. All females presented with primary or secondary amenorrhea. Growth arrest was observed in a male patient with microadenoma, whereas all the remaining patients had normal heights, and pubertal development was appropriate for their age. Spontaneous or provocative galactorrhea was observed in 12 patients (3 males and 9 females) and gynecomastia in 4 males. Mean serum PRL concentration (+/-SE) at the time of diagnosis was 1080 +/- 267 microg/L in patients with macroadenoma and 155 +/- 38 microg/L in patients with microadenoma. In 10 patients, BRC normalized PRL levels and caused variable, but significant, tumor shrinkage. CV normalized PRL concentrations and reduced tumor size in 5 patients. Cabergoline normalized PRL concentrations in 7 of 10 patients resistant to CV. Pregnancy occurred in 2 patients while on treatment. Pregnancies were uncomplicated, and the patients delivered normal newborns at term. Only 4 patients are still moderately hyperprolactinemic. Impairment of other pituitary hormone secretion was documented at the time of diagnosis in 7 patients, 5 of whom underwent surgery. Four patients became GH deficient in adult age. In conclusion, the medical treatment with dopaminergic compounds is effective and safe in patients with prolactinoma with onset in childhood, allowing preservation of the anterior pituitary function.

UI MeSH Term Description Entries
D008297 Male Males
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D011627 Puberty A period in the human life in which the development of the hypothalamic-pituitary-gonadal system takes place and reaches full maturity. The onset of synchronized endocrine events in puberty lead to the capacity for reproduction (FERTILITY), development of secondary SEX CHARACTERISTICS, and other changes seen in ADOLESCENT DEVELOPMENT. Puberties
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Prolactinomas in children under 14. Clinical presentation and long-term follow-up.
June 2015, Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Clinical profile and long term follow up of children and adolescents with prolactinomas.
January 2009, Pituitary,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Giant prolactinomas: clinical management and long-term follow up.
August 2002, Journal of neurosurgery,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Bronchiolitis obliterans in children: clinical presentation, therapy and long-term follow-up.
March 2008, Journal of paediatrics and child health,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up.
January 2009, Archives of disease in childhood,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Clinical presentation and long-term follow-up of perimyocarditis.
March 2013, Journal of cardiovascular medicine (Hagerstown, Md.),
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Long-term follow-up of stapedectomy in children and adolescents.
July 1996, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Hyperventilation syndrome in children and adolescents: long-term follow-up.
February 1981, Pediatrics,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Papillary Thyroid Carcinoma in Children and Adolescents: Long-Term Follow-Up and Clinical Characteristics.
September 2015, World journal of surgery,
A Colao, and S Loche, and M Cappa, and A Di Sarno, and M L Landi, and F Sarnacchiaro, and G Facciolli, and G Lombardi
Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
August 2002, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!